¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Accu-Chek II/IIM/III Control InVt"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® quality control ÇÑ±Û Á¤µµ°ü¸®, ǰÁú°ü¸®, Áú°ü¸®
¼³¸í   
  °úÇÐÀû ¿ø¸®¸¦ ÀÀ¿ëÇÏ¿© Á¦Ç°Ç°ÁúÀÇ À¯Áö-Çâ»óÀ» ±âÇϱâ À§ÇÑ °ü¸®. ³ÐÀº ¶æÀ¸·Î´Â °¡Àå ½ÃÀ强ÀÌ ³ôÀº Á¦Ç°À» °¡Àå °æÁ¦ÀûÀ¸·Î »ý»êÇϱâ À§ÇÑ ÀÏ·ÃÀǠü°ÔÀû Á¶Ä¡¸¦ °¡¸®Å°³ª, ÀϹÝÀûÀ¸·Î´Â ¾ÕÀÇ Á¼Àº ¶æÀÇ ÇØ¼®ÀÌ Åë¿ëµÈ´Ù. ÃʱâÀÇ QC´Â ÀüÁ¦Ç°¿¡ ´ëÇØ Ä¡¼ö-Áß·®-üÀûÀ̳ª Àç·áÀÇ È­ÇÐÀû ¼ººÐ µîÀ» ÃøÁ¤Çϰí, ±×°ÍÀ» ¹Ì¸® Á¤ÇØ ³õÀº Ç°ÁúÇ¥Áذú ºñ±³ÇÏ¿© ÀûºÎ¸¦ ÆÇÁ¤Çϴ ¹æ¹ýÀÌ ÃëÇØÁ³´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • factor III
    Á¦3ÀÎÀÚ
  • accuracy control
    Á¤È®µµ°ü¸®
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • air pollution control
    ´ë±â¿À¿°°ü¸®
  • biologics control laboratory
    »ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò
  • birth control
    »ê¾ÆÁ¦ÇÑ
  • bite control
    ±³ÇÕÁ¶Á¤
  • communicable disease control
    Àü¿°º´°ü¸®
  • conception control
    ¼öÅÂÁ¶Àý
  • control
    1. ÅëÁ¦, Á¦¾î 2. ´ëÁ¶ 3. °ü¸®
  • control analysis
    ÁöµµºÐ¼®
  • control experiment
    ´ëÁ¶½ÇÇè
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • control group
    ´ëÁ¶±º
  • control mechanism
    Á¶Àý±âÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • control
    1. ÅëÁ¦, Á¦¾î, 2. ´ëÁ¶, 3. °ü¸®
  • quality control
    Á¤µµ°ü¸®, ǰÁú°ü¸®, Áú°ü¸®
  • reflex control
    ¹Ý»çÁ¶Àý
  • safety control
    ¾ÈÀü°ü¸®
  • sugar control
    Ç÷´çÁ¶Àý
  • impulse control disorder
    Ãæµ¿Á¶ÀýÀå¾Ö, Ãæµ¿Á¶Àýº´
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • accuracy control
    Á¤È®µµ°ü¸®
  • air pollution control
    ´ë±â¿À¿°°ü¸®
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • control analysis
    ÁöµµºÐ¼®
  • biologics control
    »ý¹°Á¦Á¦°ËÁ¤
  • biologics control laboratory
    »ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò
  • birth control
    »ê¾ÆÁ¦ÇÑ
  • bite control
    ±³ÇÕÁ¶Á¤
  • control
    ÅëÁ¦, Á¦¾î, ´ëÁ¶, °ü¸®
  • case-control study
    (¢¡retrospective) ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • communicable disease control
    Àü¿°º´°ü¸®
  • conception control
    ¼öÅÂÁ¶Àý
  • control equipment
    Á¦¾îÀåÄ¡
  • control experiment
    ´ëÁ¶½ÇÇè
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • DSM-III
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 3ÆÇ
  • DSM-III-R
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 3ÆÇ °³Á¤ÆÇ
  • Sudan III
    ¼ö´Ü III
  • antithrombin III
    Çׯ®·Òºó III
  • apolipoprotein C-III
    ¾ÆÆ÷Áö´Ü¹é C-III
  • arsenazo III dye
    ¾Æ¸£¼¼³ªÁ¶<ºñ¼Ò¾ÆÁ¶> III ¿°·á
  • group III fiber
    Á¦¥²¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
  • pseudounipolar(bipolar III) disorder
    °¡¼º ´Ü±Ø¼º(¾ç±Ø¼º III)Àå¾Ö(º´).
  • AGC (automatic gain control)
    ÀÚµ¿ °ÔÀÎ Á¶Àý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antithrombin III
    Çׯ®·Òºó III
  • apolipoprotein C-III
    ¾ÆÆ÷Áö´Ü¹é C-III
  • arsenazo III dye
    ¾Æ¸£¼¼³ªÁ¶<ºñ¼Ò¾ÆÁ¶> III ¿°·á
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • oculomotor nerve (iii)
    ´«µ¹¸²½Å°æ
  • os metacarpale III ³ª
    ¼Â°¼Õ¹Ù´Ú<Áß¼ö>»À, Á¦»ïÁß¼ö°ñ(ð¯ß²ñéâ¢Íé).
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
  • pseudounipolar(bipolar III) disorder
    °¡¼º ´Ü±Ø¼º(¾ç±Ø¼º III)Àå¾Ö(º´).
  • third arch (iii)
    ¼Â°±ÁÀÌ
  • type III human T lymphotropic virus
    IIIÇü ÀÎ t¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Third arch (III)
    ¼Â°±ÁÀÌ
    [¿¾ ¿ë¾î] Á¦»ï±Ã
  • Oculomotor nerve (III)
    ´«µ¹¸²½Å°æ
    [¿¾ ¿ë¾î] µ¿¾È½Å°æ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • insect control
    °ïÃæ±¸Á¦, °ïÃæ¹æÁ¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • DNA polymerase III
    DNA Æú¸®¸Ó·¹À̽º III
  • enzyme III
    È¿¼Ò(ý£áÈ) III
  • exonuclease III
    ¿¢¼Ò´©Å¬¸®¿¡À̽º III
  • HTLV-III
    (å²) human T cell lymphostrophic virus
  • ribonuclease III
    ¶óÀ̺¸´ºÅ¬¸®¿¡À̽º III
  • acceptor control
    ¼ö¿ëü Á¦¾î (â¥é»ô÷ ð¤åÙ)
  • acceptor-control ratio
    ¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
  • adenylate control hypothesis
    ¾Æµ¥´Ò»ê(ß«)Á¶Àý¼³(ðàï½àã)
  • autogenous control
    ÀÚÀÎÁ¶Àý (í»ì×ðàï½)
  • control
    "´ëÁ¶(ÓßðÎ), Á¶Àý(ðàï½), Á¦¾î(ð¤åÙ)"
  • control analysis
    ´ëÁ¶ ºÐ¼®(ÓßðÎÝÂà°)
  • control strengh
    Á¶Àý °­µµ(ðàï½Ë­Óø)
  • negative control
    À½Á¦¾î(ëäð¤åÙ)
  • negative gene control
    À½À¯ÀüÀÚÁ¦¾î(ëäë¶îîí­ð¤åÙ)
  • positive control
    "°¡Á¶Àý(ʦðàï½), ¾ç¼ºÁ¶Àý(åÕàõðàï½)"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • AGC [=automatic gain control]
    ÀÚµ¿°ÔÀÎÁ¶Àý
  • control
    ´ëÁ¶, Á¶Àý, Á¦¾î, °ü¸®, ±ÔÁ¦, ¹æÁ¦
  • control group
    ´ëÁ¶±º
  • equipment quality control
    ÀåÄ¡ÀÇ ¼º´É°ü¸®
  • pulse control unit
    ¸Æ¹ÚÁ¶Àý´ÜÀ§
  • quality control
    È­Áú°ü¸®, ǰÁú°ü¸®
  • remote control
    ¿ø°ÝÁ¶Á¾, ¿ø°ÝÁ¶ÀÛ
  • time gain control
    ½Ã°£°ÔÀÎÁ¶Àý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
AT III angiotensin III; antithrombin III
ML I, II, III, IV mucolipidosis I, II, III, IV
BCM B-cell maturation; birth control medication; blood-clotting mechanism effects; body cell mass; body ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IIM Idiopathic inflammatory myopathies
IIM idiopathic inflammatory myopathy
A III Angiotensin III
ANG III Angiotensin III
AT III Anti-thrombin III
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Class III
    3±Þ
    µ¿ÀǾî=mesiocclusion. ÇϾǰú ÇÏ¾Ç Ä¡¾Æ°¡ »ó¾Ç¿¡ ºñÇØ Àü¹æ¿¡ À§Ä¡ÇÑ °æ¿ì.
  • class III malocclusion
    Á¦ III±Þ ºÎÁ¤±³ÇÕ
  • laminar III
    Á¦ 3Ãþ
  • lues III
    ¸Åµ¶ 3±â
    1. Èı⠸ŵ¶Àº ¸Å¿ì µå¹°´Ù. 2. ½É¸Æ°ü°è º´º¯ÀÌ 80¡­85%, ÁßÃ߽Űæ°è º´º¯ 5¡­10%, ³ª¸ÓÁö´Â °£À̳ª ´Ù¸¥ ºÎÀ§¿¡ °í¹«Á¾ÀÌ ¹ß»ýÇÑ´Ù.
  • platelet fector III
    Ç÷¼ÒÆÇ Á¦ »ï ÀÎÀÚ
  • pseudo class III
    °¡¼º III ±Þ
  • pseudotumour :

    pseudounipolar bipolar III disorder

    °¡¼º ´Ü±Ø¼º ¾ç±Ø¼º III Àå¾Ö, °¡¼º ´Ü±Ø¼º ¾ç±Ø¼º III º´
  • transverse facial fracture : µ¿ÀǾî=Le Forte III fracture.

    transverse facial vein

    °¡·Î ¾ó±¼ µ¿¸Æ
  • true class III
    Áø¼º III±Þ ºÎÁ¤ ±³ÇÕ
  • type III
    3Çü
  • admission by legal control
    Á¶Ä¡ ÀÔ¿ø
  • birth control
    ÇÇÀÓ¹ý
    ¼öŸ¦ ÀΰøÀûÀ¸·Î Á¶ÀýÇÏ´Â ÀÏ. Àü¿¡´Â »ê¾Æ Á¦ÇÑ, Ãâ»ê Á¶ÀýÀ̶ó°í ÇßÀ¸³ª Á¶Àý ´ë»óÀº ºÐ¸¸ÀÌ ¾Æ´Ï°í ¼öÅÂÀ̱⠶§¹®¿¡ ¼öÅ Á¶Àý·Î °³Á¤µÇ¾ú´Ù. ¸ðüÀÇ °Ç°­À̳ª °æÁ¦ÀûÀÎ ÀÌÀ¯ µîÀ¸·Î ÀÓ½ÅÇØ¼­´Â °ï¶õÇÑ »çÁ¤ÀÌ ÀÖÀ» ¶§ ÇÇÀÓÀ» °è¼ÓÇϰí, ¾ÆÀ̰¡ ÇÊ¿äÇØÁö¸é ÇÇÀÓÀ» ÁßÁöÇϰí ÀÓ½ÅÇÒ ¼ö ÀÖµµ·Ï ÀÎÀ§ÀûÀÎ ¼ö´ÜÀ» »ç¿ëÇØ¼­ ¼öŸ¦ ÀΰøÀûÀ¸·Î Á¶ÀýÇÏ¿© »ê¾Æ¸¦ Á¦ÇÑÇÏ´Â °ÍÀÌ´Ù. ÀÌ¹Ì ÀÓ½ÅÇÑ °ÍÀ» ÀΰøÀûÀ¸·Î ÁßÀýÇÏ´Â °ÍÀº ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾Ê´Â´Ù. Áï, ÇÇÀÓÀÇ ½ÇÆÐ´Â µµ¸®°¡ ¾ø±â ¶§¹®¿¡ ¹Ù¸¥ ÇÇÀÓÀÇ Áö½ÄÀ» ¾ò¾î ÀûÀýÇÑ ÇÇÀÓ¹ýÀ» ¼±ÅÃÇØ¼­ ¹Ù¸£°Ô ½ÃÇàÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù. ¼öÅ Á¶Àý¿¡ ÀÀ¿ëµÇ´Â ÇÇÀÓ¹ýÀº ¼öÁ¤ ÀúÁö¹ý°ú ¼öÅ ÀúÁö¹ýÀ¸·Î ´ëº°µÇÁö¸¸ ¸ðµÎ ÀϽÃÀûÀÎ ÇÇÀÓ¹ýÀÌ´Ù. À̰ÍÀº ±¹°¡°¡ ÁÖüÀÎ °æ¿ì¿¡´Â Àα¸ Á¤Ã¥ÀÌ µÇ¸ç, °¡Á¤ÀÌ ÁÖüÀÎ °æ¿ì¿¡´Â °¡Á· °èȹÀÌ µÇ´Â °¡Àå ÇÕ¸®ÀûÀÎ ¼ö´ÜÀÌ´Ù. ½Ç¿ëÀûÀÎ ¸é¿¡¼­ ºÐ·ùÇÑ ÇÇÀÓ¹ýÀº ´ÙÀ½°ú °°´Ù. ¡¼¹è¶õÀÏ ÀüÈÄÀÇ ¼º±³¸¦ ÇÇÇÏ´Â ¹æ¹ý¡½ ¹è¶õÀÏ ÀüÈÄ ¼öÀϰ£À» ±Ý¿åÇÔÀ¸·Î½á ¼öÁ¤À» ¹Ì¸® ¸·´Â °ÍÀ¸·Î, ¹è¶õÀÏÀ» ¿¹»óÇÏ´Â ¹æ¹ý¿¡´Â 2°¡Áö°¡ ÀÖ´Ù. ¨ç ¿À±â³ë½Ä ¼öÅ Á¶Àý¹ý : Çѱ¹¿¡¼­ °¡Àå ³Î¸® º¸±ÞµÇ¾î ÀÖ´Â ¹æ¹ýÀ¸·Î, ¿ù°æ ÁֱⰡ Á¤È®ÇÏ°Ô µ¹¾Æ¿À´Â ¿©¼º¿¡°Ô¸¸ Àû¿ëÀÌ °¡´ÉÇÏ´Ù. 28ÀÏÇüÀÎ ¿©¼ºÀÇ °æ¿ì ¿ù°æ Á¦1ÀϰºÎÅÍ ¼¼¾î¼­ Á¦14Àϰ°¡ µÇ´Â ³¯ÀÇ Àü 3Àϰ£°ú ÈÄ 2Àϰ£ÀÌ °¡Àå ÀÓ½ÅÇϱ⠽¬¿î ³¯·Î º¸°í ÀÌ ±â°£Àº ¼º±³¸¦ ÇÇÇÑ´Ù. ÀÌ ¹æ¹ýÀº ¿ù°æ ÁֱⰡ ºÒ±ÔÄ¢ÇÑ ¿©¼ºÀÇ °æ¿ì¿¡´Â ½ÇÆÐÀÇ È®·üÀÌ Å©´Ù. ¨è ±âÃÊ Ã¼¿ÂÇ¥¸¦ ÀÀ¿ëÇÏ´Â ¹æ¹ý : ¸ÅÀÏ ±âÃÊ Ã¼¿ÂÀ» ÃøÁ¤Çؼ­ ±âÃÊ Ã¼¿Â °î¼±ÀÌ °í¿Â»óÀÌ µÇ¾î 2ÀÏÀÌ °æ°úÇßÀ» ¶§´Â °ÅÀÇ ÀÓ½ÅÇÏÁö ¾Ê´Â °ÍÀ¸·Î ³ªÅ¸³ª ÀÖ¾î 3ÀÏ ÀÌÈĺÎÅÍ ¼º±³¸¦ °®´Â ¹æ¹ýÀÌÁö¸¸, °í¿Â»óÀÎÁö Àú¿Â»óÀÎÁö¸¦ Á¤ÇϱⰡ ¶§·Î´Â °ï¶õÇÑ ¶§°¡ ÀÖ´Ù. ¡¼³²¼ºÀÌ ÇÇÀÓ µµ±¸³ª ¾àǰÀ» »ç¿ëÇÏ´Â ¹æ¹ý¡½ ³²¼ºÀÌ ¼º±³ ¶§ Äܵ¼À» ½á¼­ ¼öÁ¤À» ÀúÁöÇÏ´Â ¹æ¹ýÀÌ °¡Àå ÀϹÝÀûÀÌ´Ù. Äܵ¼Àº ³²¼º ¼º±â¿¡ ¾º¿ö¼­ »ç¿ëÇÏ´Â ¾ãÀº °í¹« Á¦Ç°ÀÎ Á¡¿¡¼­ ³²¼ºÀÌ »ç¿ë°¨À» °¡Áö°Ô ÇÑ´Ù´Â °áÁ¡ÀÌ ÀÖ°í, ¿©¼º¿¡°Ô´Â ½É¸®ÀûÀÎ ¹®Á¦¸¦ Æ÷ÇÔÇÏ¿© ¿©·¯ °¡Áö °áÁ¡ÀÌ ÁöÀûµÇ°í ÀÖÁö¸¸, ½ÇÆÐÀ²ÀÌ ³·°í ÀϹÝÀûÀ¸·Î ½±°Ô ±¸ÇÒ ¼ö ÀÖÀ¸¸ç ´©±¸³ª »ç¿ëÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÌ ´Ù¸¥ ¹æ¹ý¿¡ ºñÇØ ÀåÁ¡ÀÌ´Ù. ƯÈ÷ ÃÖ±Ù¿¡´Â °í¹«ÀÇ ÁúÀÌ °³·®µÇ°í Á¦Ç°ÀÇ Ç°ÁúÀÌ Çâ»óµÇ¾î ÆÄ¼ÕÀÇ ¿ì·Áµµ ¾ø´Ù. ÀÌ ¹Û¿¡ Á¤ÀÚ¸¦ ¸¸µå´Â ÈûÀ» ¾àÈ­½Ãų ¸ñÀûÀ¸·Î ³²¼º¿¡°Ô ÇÇÀÓ ¾àÀ» ¾²°Ô ÇÏ´Â °æ¿ìµµ ÀÖÀ¸³ª, ÇÇÀÓÀÇ ¸ñÀûÀº ´Þ¼ºÇß´Ù ÇØµµ °¡²û ³²¼ºÀÇ ¼º¿åÀ» ÀúÇϽÃŲ´Ù ÇÏ¿© ½Ç¿ëµÇÁö ¾Ê°í ÀÖ´Ù. ¡¼ÁßÀý ¼º±³¹ý¡½»çÁ¤ Àü¿¡ ¼º±³¸¦ Áß´ÜÇϰí Áú ¿ÜºÎ¿¡ »çÁ¤ÇÏ´Â ¹æ¹ýÀε¥ Áú ¾È¿¡ Á¤¾×À» µé¿©º¸³»Áö ¾Êµµ·Ï ÇØ¼­ ÀÓ½ÅÀ» ÇÇÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. ÀÌ ¹æ¹ýÀº Ưº°ÇÑ ±â±¸¸¦ ÇÊ¿ä·Î ÇÏÁö ¾ÊÀ¸¸ç ¾î·Á¿ò ¾øÀÌ ÇÒ ¼ö ÀÖ´Â ÀåÁ¡µµ ÀÖÁö¸¸, ÇÇÀÓÀ̶ó´Â ¸ñÀû ¶§¹®¿¡ ¼º°¨À» Èñ»ýÇÏ°Ô µÇ´Â °æÇâÀÌ °­ÇÏ´Ù. ´õ¿íÀÌ °áÁ¤ÀûÀÎ °áÁ¡Àº ÀÓ½ÅÀÇ À§Çèµµ Å©´Ù´Â Á¡ÀÌ´Ù. ¡¼¿©¼ºÀÌ ±â±¸¸¦ »ç¿ëÇÏ´Â ¹æ¹ý¡½¨ç Æä¼­¸®
  • bite control
    ±³ÇÕ Á¶Á¤
    ±³ÇÕ°£ °ü°è³ª ±× Ç¥½Ã¸¦ Á¶Á¤ÇÏ´Â °Í.
  • case control study
    ȯÀÚ ´ëÁ¶ ¿¬±¸
  • control animal
    ´ëÁ¶ µ¿¹°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
angiotensin III <chemical> A heptapeptide formed by the enzymatic hydrolysis of angiotensin II. It has greater activity than angiotensin II for stimulating aldosterone synthesis and in the release of prostaglandins but only 20% of the pressor activity.
Chemical name: Angiotensin II, 1-de-L-aspartic acid-
(12 Dec 1998)
annexin III <enzyme> A protein of the annexin family that catalyses the conversion of 1-d-inositol 1,2-cyclic phosphate and water to 1-d-myo-inositol 1-phosphate.
Chemical name: 1-D-myo-Inositol-1,2-cyclic-phosphate 2-inositolphosphohydrolase
Registry number: EC 3.1.4.36
(12 Dec 1998)
antithrombin III <haematology> Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream.
Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III.
Conditions that may have an associated low value of antithrombin III include: liver disease and DIC. Normal values are: 0.20 to 0.45 mg/ml or more than 50% of the laboratory control value.
Conditions where there is a deficiency of this important protease inhibitor can result in a condition of hypercoagulation, resulting in an increased risk for blood clot formation.
Inheritance: autosomal dominant.
(13 Jan 1998)
apolipoprotein C-III <biochemistry> An apolipoprotein found in VLDL, HDL, and chylomicrons.
(05 Mar 2000)
arsenazo III <chemical> Metallochrome indicator that changes colour when complexed to the calcium ion under physiological conditions. It is used to measure local calcium ion concentrations in vivo.
Pharmacological action: dyes, indicators and reagents.
Chemical name: 2,7-Naphthalenedisulfonic acid, 3,6-bis((2-arsonophenyl)azo)-4,5-dihydroxy-
(12 Dec 1998)
arteriae intercostales posteriores III-XI posterior intercostal arteries 3-11
band III protein <protein> A 90 kD protein embedded in the surface of the human erythrocyte membrane, identified as the major anion transport/exchange protein. When the red blood cell is in the lungs, brings chlorine ion into the cell in exchange for bicarbonate.
Analogous proteins exist in other erythrocytes. A dimeric transmembrane glycoprotein, with binding sites for many cytolasmic proteins, including ankyrin, on its cytoplasmic domain.
(18 Nov 1997)
palpebra III The semilunar fold formed by the palpebral conjunctiva at the medial angle of the eye, a fold of the conjunctival mucous membrane found in many animals; normally partially hidden in the medial canthus of the eye when at rest, it may be extended to cover part or all of the cornea in a winking-like action to clean the cornea, as in birds.
Synonym: membrana nictitans, nictitating membrane, palpebra III, palpebra tertia, third eyelid.
Synonym: plica lunata, plica semilunaris of eye, semilunar conjunctival fold.
(05 Mar 2000)
ramus collateralis arteriarum intercostalium posteriorum III-XI Branch arising near angle of rib and descending to run along superior border of rib below; distribution: lower half of intercostal spaces 3-11; anastomoses: collateral branches of anterior intercostal arteries.
Synonym: ramus collateralis arteriarum intercostalium posteriorum III-XI.
(05 Mar 2000)
ramus cutaneus medialis rami dorsalis arteriarum intercostalium posteriorum III-XI Medial cutaneous branch of dorsal branch of posterior intercostal arteries.
See: medial cutaneous branch.
(05 Mar 2000)
ramus dorsalis arteriarum intercostalium posteriorum III-XI Terminal branch (with ventral branch) of the 3rd through 11th posterior intercostal arteries, distributed to thoracic portion of posterior vertebral column, spinal cord and environs, and back.
Synonym: ramus dorsalis arteriarum intercostalium posteriorum III-XI.
(05 Mar 2000)
malocclusion, angle class III Malocclusion in which the mandible is anterior to the maxilla as reflected by the first relationship of the first permanent molar (mesioclusion).
(12 Dec 1998)
virus III of rabbits An obsolete name for a latent herpesvirus infection of rabbits.
Origin: the third strain isolated, used for study
(05 Mar 2000)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
grade III astrocytoma <tumour> Astrocytoma of intermediate grade.
See: glioblastoma multiforme.
(05 Mar 2000)
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 1 ÆäÀÌÁö: 1
  • Accu-Chek II/IIM/III Control InVt - »õâ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • invt.
    inventory
  • bring under control
    Á¦¾î(¾ïÁ¦)ÇÏ´Ù; (ºÒÀ»)²ô´Ù
  • control
    ¾ïÁ¦ÇÏ´Ù,°ü¸®ÇÏ´Ù,Áö¹è,¾ïÁ¦
  • self-control
    ÀÚÁ¦
  • atomic control
    ¿øÀÚ·Â °ü¸® 
  • atonic control
    ¿øÀڷ°ü¸® 6
  • automatic train control
    ¿­Â÷ÀÚµ¿Á¦¾îÀåÄ¡
  • birth control
    »ê¾Æ Á¦ÇÑ
  • central control station
    Áß¾ÓÁ¦¾î±¹
  • civilian control
    ¹®°ü ¿ìÀ§(Áö¹è)
  • conception control
    ¼öÅ Á¶Àý;ÇÇÀÓ
  • control
    Áö¹è;´Ü¼Ó;°ü¸®;°¨µ¶(±Ç);¾ïÁ¦;Á¦¾î;±ÔÁ¦;Á¦±¸(·Â);ÄÁÆ®·Ñ;ÅëÁ¦(°üÁ¦)¼ö´Ü;(±â°èÀÇ)Á¶Á¾(Á¦¾î)ÀåÄ¡;(½ÇÇèÀÇ)´ëÁ¶Ç¥ÁØ;´ëÁ¶±¸;¿µ¸Å¸¦ Áö¹èÇÏ´Â Áö¹è·É;(ÀÚµ¿Â÷°æÁֵ¼­ °£´ÜÇÑ ¼ö¸®¸¦ À§ÇÑ)°æÁÖ Áߴܱ¸¿ª;Á¦¾î;Áö¹èÇÏ´Ù;ÅëÁ¦(°üÁ¦)ÇÏ´Ù;°¨µ¶ÇÏ´Ù;°ü¸®ÇÏ´Ù;¾ïÁ¦(Á¦¾î)ÇÏ´Ù;(
  • control board
    Á¦¾î¹Ý
  • control booth
    (¶óµð¿À.TV)Á¦¾î½Ç;Á¶Á¤½Ç
  • control chart
    °ü¸®µµ(ƯÈ÷ Á¦Ç° ǰÁúÀÇ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á